Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.
Ontology highlight
ABSTRACT: Tumor necrosis factor alpha (TNFα) is a potent antitumoral cytokine, either killing tumor cells directly or affecting the tumor vasculature leading to enhanced accumulation of macromolecular drugs. Due to dose limiting side effects systemic administration of TNFα protein at therapeutically active doses is precluded. With gene vectors, tumor restricted TNFα expression can be achieved and in principle synergize with chemotherapy. Synthetic gene carriers based on polyamines were intravenously injected, which either passively accumulate within the tumor or specifically target the epidermal growth factor receptor. A single intravenous injection of TNFα gene vector promoted accumulation of liposomal doxorubicine (Doxil) in murine neuroblastoma and human hepatoma by enhancing tumor endothelium pe
SUBMITTER: Su B
PROVIDER: S-EPMC3594014 | biostudies-literature | 2013 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA